WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today reported 2015 first-quarter financial results, including revenue from Jakafi® (ruxolitinib). As well as the strong performance of Jakafi in the quarter, the Company highlighted the successful result of the second baricitinib Phase III trial in rheumatoid arthritis, as announced with Lilly, and the publication, in the New England Journal of Medicine, of the Phase III RESPONSE trial results of Jakafi in patients with uncontrolled polycythemia vera (PV).
Help employers find you! Check out all the jobs and post your resume.
